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High transplant cell loss is a major barrier to translation of stem cell therapy for pathologies 
of the brain and spinal cord. Encapsulated delivery of stem cells in biomaterials for cell 
therapy is gaining popularity but experimental research has overwhelmingly used laboratory 
grade materials unsuitable for human clinical use - representing a further barrier to clinical 
translation. A potential solution is to use neurosurgical grade materials routinely used in 
clinical protocols which have an established human safety profile. Here, we tested the ability 
of Duragen PlusTM - a clinical biomaterial used widely in neurosurgical duraplasty 
procedures, to support the growth and differentiation of neural stem cells- a major transplant 
population being tested in clinical trials for neurological pathology. Genetic engineering of 
stem cells yields augmented therapeutic cells, so we further tested the ability of the Duragen 
PlusTM matrix to support stem cells engineered using magnetofection technology and 
minicircle DNA vectors- a promising cell engineering approach we previously reported 
(Journal of Controlled Release, 2016 a &b). The safety of the nano-engineering approach 
was analysed for the first time using sophisticated data-independent analysis by mass 
spectrometry-based proteomics. We prove that the Duragen PlusTM matrix is a promising 
biomaterial for delivery of stem cell transplant populations, with no adverse effects on key 
regenerative parameters. This advanced cellular construct based on a combinatorial nano-
engineering and biomaterial encapsulation approach, could therefore offer key advantages 
for clinical translation.  
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Injury in the central nervous system (CNS) is associated with a complex, multifaceted 
pathology [1,2] and it is widely believed that combinatorial therapies targeting multiple 
therapeutic targets are needed to promote effective repair. Numerous preclinical studies 
have demonstrated improved functional and histological outcomes following transplantation 
of genetically engineered neural stem cells (NSCs). Potential mechanisms include 
replacement of cells lost to the injury processes, release of pro-regenerative factors and 
additional expression of therapeutic proteins, for example, neurotrophic factors to encourage 
nerve fibre growth or enzymes to break down glial scar constituents [3–8]. Phase I/II trials 
investigating NSC transplantation for stroke and amyotrophic lateral sclerosis are ongoing [9] 
demonstrating the potential to translate these approaches into the clinic. Despite this 
promise, a major barrier to translation of neural cell therapy is the high cell loss that occurs 
post-transplantation into the CNS, due to factors such as high mechanical forces and cell 
clumping during delivery through fine gauge needles and cell washout from lesion sites. In 
general, < ca 3% of cells will be engrafted post-transplantation [10,11] with one study 
showing that no transplanted fetal neuroepithelial stem cells survived at three days post-
transplantation [12]. These issues pose major clinical challenges as high cell death reduces 
the efficacy of the therapy, could induce secondary inflammatory responses and increase 
expense due to higher cell numbers needed for initial transplantation procedures.  
Such factors have led to a major drive to develop biomaterial based delivery technology 
deploying implantable and protective scaffolds for stem cell delivery. Functional neurological 
improvement has been shown after encapsulated NSC delivery into various rodent models 
of CNS injury/disease. Poly lactic-co-glycolic acid (PLGA) scaffolds protected NSC 
transplants in a rat lateral hemisection injury model leading to improved locomotion whereas 
NSCs transplanted alone led to scarring, cyst formation and poorer behavioural outcomes 
[13]. Using a fibrin matrix, human NSCs were successfully implanted into complete 
transecting injuries in rats leading to axon extension from the graft and from the host tissue 
with improved behavioural scores compared to no graft implantation [14]. Gelfoam scaffolds 
[15], porous collagen scaffolds [16] and 3D gelatin-electrospun poly (lactide-co-
glycolide)/PEG scaffolds [17] all improved functional recovery when used to deliver NSCs 
into rat models of SCI. Critically, however, such biomaterials are not yet clinically approved 
and lack the scalable manufacturing processes needed for adoption into clinical practice. 
This is a major issue as the FDA estimate that on average new biomaterial scaffolds take 
seven years to proceed through FDA-approval [18].  
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Neurosurgical grade biomaterials which have been approved for human use could offer a 
suitable potential alternative. In particular, Duragen PlusTM matrix is a medically approved, 
neurosurgical grade biomaterial derived from Type I bovine collagen, and predominantly 
used in duraplasty procedures. Here, it allows for the infiltration of fibroblasts for restoration 
and repair of the dura mater following a breach made intraoperatively and is reported to be 
resorbed after six to eight weeks [19]. The material is reported to lack immunogenicity, 
cytotoxicity and pyrogenicity and is conformable, sterile and biocompatible [20]. Duragen 
PlusTM has been implanted into the nervous system with no adverse effects noted and 
supports neural cell growth, including that of rat cortical neurons [21]. Despite these critical 
advantages, the application of Duragen PlusTM to support encapsulation of stem cells for 
NSC therapy has never been evaluated.  
We have tested the utility of the Duragen PlusTM matrix to support incorporation and growth 
of unmodified NSCs, and those genetically nanoengineered with magnetic nanoparticles and 
minicircle DNA vectors. Our aims are to (i) examine whether NSCs can be propagated in the 
neurosurgical grade biomaterial scaffold; (ii) confirm the safety of nanoengineering NSCs 
with subsequent incorporation into Duragen PlusTM using histological assays and mass 
spectrometry coupled with bioinformatics. 
2. Results 
2.1. Structural Characterisation of Duragen PlusTM 
Duragen PlusTM demonstrated the ability to rapidly absorb tissue culture medium (within 5-10 
seconds) (Figures 1a-b) indicating a highly porous matrix structure. From a gross visual 
assessment, ca. 25-40% volumetric expansion of the material was observed as the medium 
was absorbed. Under light microscopy, Duragen PlusTM demonstrated an obvious, highly 
porous structure (Figure 1c). In preliminary experiments, clusters of NSC nuclei could be 
easily detected within the material pores after seeding cells directly onto the matrix (Figure 
1d). Scanning electron microscopy (SEM) of Duragen PlusTM confirmed its highly porous 
structural network (Figures 1e-f) with variable pore sizes whose average size was 25.93 ± 




Figure 1: Porous Duragen PlusTM structure demonstrates cell infiltration and 
attachment. (a) Dry Duragen PlusTM sample before processing. (b) Duragen PlusTM after 
application of cell medium demonstrates fluid absorption with evidence of swelling. (c) 
Duragen PlusTM under light microscopy demonstrates an obvious porous structure. (d) 
Clusters of NSC nuclei could be observed which appear to infiltrate these pores and adhere 
to the Duragen PlusTM matrix fibres. (e) and (f) SEM at x100 magnification and x1000 
magnification respectively show the highly porous structure of Duragen PlusTM.  
 
2.2 NSCs showed high viability and normal “stemness”, proliferative capacity and 
differentiation in Duragen PlusTM 
To assess the safety of the biomaterial for NSC growth, assays of live and dead cells along 
with counts of pyknotic nuclei were carried out at early (24 h), intermediate (eight days) and 
late (12 days) time points. Pyknosis (defined as the condensation of chromatin within the 
nucleus caused by necrosis or apoptosis) was detected by evidence of a hyperdense, small 
and/or fragmenting nucleus [22]. NSCs and differentiated cells displayed high cell viability 
across all time points (≥87.0 ± 3.74%) and a low proportion of pyknotic nuclei (≤7.48 ± 
1.51%) (Figures 2a, c-d). There was no significant difference between the proportions of 
live cells or pyknotic nuclei in Duragen PlusTM at any time point examined. 
In Duragen PlusTM, a high proportion of nuclei were positive for nestin, an NSC cytoskeleton 
marker (93.87 ± 2.84%) and Sox-2, an NSC-specific transcription factor (95.53 ± 0.42%) at 
48 h. Cells demonstrated typical NSC morphologies with bipolar processes and were 
associated with round, healthy appearing nuclei (Figure 2e-f). SEM confirmed the presence 
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of clusters of neurospheres, clearly incorporated within the Duragen PlusTM matrix (Figure 
2b). At all time points investigated, there was clear evidence of cell proliferation (Figures 
2f&h and Figures 2g&h)). At 24 h, 25.59 ± 4.07% of cells expressed the proliferation 
marker, EdU (Figure 2f). This significantly decreased to 7.21 ± 1.41% at eight days once the 
cells had differentiated. The majority of cells (ca. 70%) that showed EdU labelling in the 
differentiated population were identified as GFAP positive astrocytes (Figure 2g). NSCs and 
their differentiated progeny appeared to be evenly distributed throughout the 3D depth of the 
matrix with similar numbers of cells counted at each plane of analysis (PoA) and no 
statistical differences detected between these (Figures 2i-j). 
Six days after induction of differentiation (eight days growth in Duragen PlusTM), the three 
major classes of daughter cells of NSCs, viz. neurons, astrocytes and oligodendrocytes were 
all observed within the biomaterial matrix. The highest proportion (79.58 ± 6.28%) of cells 
was that of astrocytes which demonstrated characteristic stellate morphologies (Figure 3a). 
18.61 ± 5.10% of cells were of the neuronal lineage, staining for the neuronal marker Tuj1 
(Figure 3a). The smallest proportion of cells were oligodendrocytes, staining positive for 
MBP (2.12 ± 0.96%) which displayed highly branched morphologies often extending into 
multiple planes within the biomaterial matrix (Figure 3a). The relative proportions of each 
cell type generated were similar across all examined time points (Figure 3b). Neurons 
demonstrated evidence of cellular maturation across the time period examined displaying 
increasing complexity in their networks (Figure 3a) and a statistically significant increase in 




Figure 2: Duragen PlusTM supports NSC survival, maintenance of stem cell phenotype 
and proliferation in a 3-D matrix. (a) Representative fluorescence image at 24 h 
demonstrating live cells stained with calcein and dead cells stained with ethidium 
homodimer-1 (arrows indicate dead cells). The insert is a counterpart image showing the 
nuclei stained with Hoechst dye. Scale bar = 50 μm. (b) SEM image of NSCs growing in 
Duragen PlusTM matrix at 48 h. Scale bar = 15 μm. (c) Bar graph displaying cell viability 
within Duragen PlusTM across all time points. The difference between time points was not 
significant (p-value = 0.179, one-way ANOVA, n=3). (d) Bar graph displaying proportions of 
pyknotic nuclei detected in NSCs grown within Duragen PlusTM across all time points. The 
differences between time points were not significant (p-value = 0.297, one-way ANOVA, 
n=3). (e) Representative fluorescence image of Sox-2 staining of NSCs in Duragen PlusTM. 
95.5 ± 0.42% of cells were positive for Sox-2 at 48 h (n=3). Scale bar = 10 μm. (f) 
Representative fluorescence images demonstrating proliferation of NSCs (nestin positive 
cells) observed at 24 h in Duragen PlusTM, arrows indicate proliferating NSCs, scale bars = 
50 μm and (g) proliferation of differentiated cells. Arrow indicates a proliferating astrocyte in 
the biomaterial matrix (GFAP positive cell). (h) Bar chart showing numbers of proliferating 
cells detected within Duragen PlusTM at 24 h and 8 days (**p-value < 0.01, two sample T 
test, n=3). Graphs (i-j) demonstrate 3-D distribution of cells throughout the Duragen PlusTM 





Figure 3: Duragen PlusTM supports NSC differentiation and maturation of daughter 
astrocytes, neurons and oligodendrocytes. (a) Representative fluorescence image panel 
demonstrating maturation of astrocytes, neurons and oligodendrocytes at day eight, 12 and 
16 in Duragen PlusTM. Scale bar = 25 μm. Bar graph (b) demonstrates the differentiation 
profile of NSCs in Duragen PlusTM. (c) Axon length increased two-fold from day eight to day 
16. Statistical difference is: *p-value < 0.05 (one-way ANOVA with Bonferroni multiple 
comparison tests, n=3). 
 
2.3 Duragen PlusTM supports growth of genetically nano-engineered NSCs: cell engineering 
protocols show minimal impact on NSC molecular profiles 
Neurospheres were magnetofected with GFP encoding minicircles using our previously 
developed procedures [23,24]. At 24 h post-transfection, the engineered NSC population 
was split into parallel experiments for proteomic analysis or for incorporation into Duragen 
PlusTM by direct seeding into the matrix. At 24 h after seeding (48 h after transfection), GFP 
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production was observed in NSCs within the Duragen PlusTM matrix (Figure 4a-d), indicating 
transfection processes continued as expected within the biomaterial matrix. Due to the high 
density of NSCs within neurospheres, individual NSCs expressing GFP could not be 
identified for quantification purposes. However, it was observed that a high proportion of 
neurospheres within Duragen PlusTM demonstrated at least one NSC showing GFP 
production, detected by an anti-GFP antibody (82.03 ± 3.55%).  
The other subset of engineered NSCs were lysed at two and four days after magnetofection 
for proteome analysis using SWATH-MS data independent acquisition (DIA). Comparison 
between treated and untreated control cells made using Principal Components Analysis 
(OneOmics platform) (Figure 4e) demonstrates similarity of the samples. The litter from 
which the cells were harvested was the greatest differentiator between samples, followed by 
the number of days post-harvest. High technical reproducibility of each triplicate injection 
was observed, with close clustering of technical replicates (Figure 4e). Detailed investigation 
of the proteins identified by SWATH-MS further indicated that few system-wide changes 
were observed following magnetofection with minicircle vectors (Figure 4f-g). These 
changes were fewer in number than those delineating cells at day four of the experiment vs. 
day two (Figure 4h). The full list of putatively differentially-expressed proteins is provided as 
supplementary tables 1-4. Whilst most of the proteins identified have no known association 
with NSC viability, proliferation or differentiation (factors that we consider key for effective 
transplantation), a downregulation of GFAP (-2.4-fold, p=0.002) was observed in transfected 
NSCs compared to control NSCs at day four. This was less pronounced than the alteration 





Figure 4: Proteomic analysis of NSCs reveals minicircle/nanoparticle safety for 
engineering of pre-incorporated cells. (a-d) Representative counterpart fluorescence 
images of minicircle magnetofected NSCs in Duragen PlusTM, 48 h after transfection: (a) 
GFP production (b) anti-GFP antibody (aGFP) detecting GFP production, (c) double merged 
image displaying GFP expression detectability increased by the anti-GFP antibody and (d) 
triple merged image demonstrating the proportion of NSCs producing GFP within the 
Duragen PlusTM matrix. Arrowheads indicate NSCs producing GFP (green) and stained 
positive for anti-GFP (red). Scale bar = 50 μm. (e) Principal Components PC1/PC2 plot of 
global patterns of protein expression. Clusters labelled L1-L3 show results obtained from 
individual litters. Blue = Control Day 2; green = minicircle-MNP-treated, Day 2; orange = 
control day 4; red = minicircle-MNP-treated day 4. (f-h) Volcano plots plotted as log2 most 
likely ratio fold-change vs. –log10 p value. Significantly dysregulated proteins (p<0.01, ≥2-fold 
change at 65% confidence, 0.2 reproducibility, excluding single peptides) are shown in red. 
Changes between untreated and treated NSCs at (f) day 2 and (g) day 4; (h) observed 




2.4 Histological analysis of genetically engineered NSCs propagated in Duragen PlusTM 
demonstrates protocol safety and retention of transgene expression 
After 24 h growth in Duragen PlusTM, the transfected NSC population demonstrated high 
viability (92.83 ± 2.09%) equivalent to that of the control (95.67 ± 2.18%) (Figure 5a&c). 
Further, there was no statistical difference in the proliferation rates of the transfected NSC 
population versus the control population (Figure 5b&d). At this time point, the majority of 
cells were positive for nestin and sox-2, with no differences in the proportions of cells 
labelled with these markers between transfected and control conditions (Figure 5e-h). >95% 
of GFP producing cells at 48 h post transfection were NSCs as evidenced by GFP co-
localisation with NSC marker expression. NSC morphologies were also similar across 
transfected and control groups (Figure 5e&f). After differentiation (ten days post 
transfection, eight days post seeding into Duragen PlusTM), all three differentiated cell types 
were present in the matrix with no differences in the proportions of each cell type when the 
transfected population were compared to the control population (Figure 6a-d). GFP 
production in Duragen PlusTM was noted up to day ten post transfection in astrocytes, the 
latest time point examined (Figure 6a).  
 
 
Figure 5: NSC viability, proliferation and stemness unaffected following 
nanoengineering and incorporation into Duragen PlusTM. (a) Representative 
fluorescence image of live/dead stained, transfected NSCs in Duragen PlusTM at 48 h post 
transfection/ 24 h post-seeding in to Duragen PlusTM displaying high viability with no 
difference to controls (p-value = 0.392, two sample T-test, n=4). (b) Representative 
fluorescence image of transfected NSCs (arrows) in Duragen PlusTM at 48 h post 
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transfection/ 24 h post-seeding in to Duragen PlusTM. (e-f) Transfected NSCs within Duragen 
PlusTM demonstrating a high proportion of nestin positive cells (e) and sox-2 positive cells (f). 
Arrows indicate GFP producing NSCs. (a-f) Scale bars = 25 μm. Bar graphs (c-h) 
demonstrate proportions of (c) viable cells at day 2, (d) cells proliferating at day 2, (g) cells 
expressing nestin at day 2, and (h) cells expressing sox-2 at day 2. No significant differences 
(p>0.05) between transfected and control NSC populations in Duragen PlusTM were noted 
(n=4). 
 
Figure 6: NSCs retain the ability to differentiate into their daughter cells with 
continued transgene expression within Duragen PlusTM. Representative fluorescence 
images (a-c) of differentiated transfected NSCs: astrocytes (a), neurons (b) and 
oligodendrocytes (c) display normal morphologies within the construct at ten days post 
transfection/ nine days post-seeding in to Duragen PlusTM. Arrows indicate GFP producing 
cells with the morphological appearance of astrocytes. (a-c) Scale bar = 25 μm. Bar graph 
(d) demonstrates relative proportions of each cell type in transfected and control populations. 
Proportions of each cell type do not differ between control and transfected cells (p-values > 




This is the first demonstration of the capacity of a neurosurgical grade biomaterial to support 
the growth of NSCs- a major neural transplant population for clinical applications. Our data 
support the concept that this clinical biomaterial could be used as a cell delivery matrix in 
neural cell therapy. Laboratory grade biomaterials have been shown to successfully support 
stem cell growth in vitro, with NSCs demonstrating cell survival, normal phenotypic 
expression and importantly differentiation into neurons in fibrin hydrogels [25], 3D gelatin-
electrospun poly (lactide-co-glycolide)/ polyethylene glycol (PEG) scaffolds [17] and poly (L-
lactic acid) nanofibers [26]. Functional neurological improvement was reported with NSCs in 
vivo when cultured in a fibrin matrix [14,27], poly lactic-co-glycolic acid (PLGA) scaffold 
[13,28], gelfoam scaffold [15], porous collagen scaffold [16] and 3D gelatin-electrospun poly 
(lactide-co-glycolide)/PEG scaffolds [17]. However, these biomaterials are not tested for 
human use, therefore rigorous trials would be essential prerequisites before clinical 
translation can be envisaged. 
Duragen PlusTM by contrast offers the major benefit that it is pre-approved by the FDA for 
surgical use. The biomaterial is designed to be pliable for surgical use, allowing it to be 
moulded to lesions varying in size and shape. The material is porous, facilitating repair 
processes such as cellular infiltration and vascularisation [29] and to date has no recorded 
immune rejection events, indicating a strong safety profile. To facilitate regrowth, a scaffold 
needs to degrade, ideally over a two-to four-month window [30]. Duragen PlusTM when 
utilised as a dural substitute degrades over a period of two months highlighting its suitability 
for neurological applications [29]. We have shown that NSCs grown within Duragen PlusTM 
display high survival, maintenance of stem cell phenotype, continued proliferation and 
differentiation into all three daughter cell types (without alteration of cell fate), demonstrating 
the safety of the material. The counts of differentiated NSCs are in the expected proportions 
as previously observed on standard culture substrates [23,24].  
Further, genetically engineered NSCs have been incorporated into the matrix, facilitating 
potential combinatorial therapy for cell replacement and functional protein delivery into injury 
sites- highlighting the advantages offered by this material. We have previously discussed 
that the pathological microenvironment of neural injury sites limits tissue regeneration. 
Manipulation of injury foci to a pro-regenerative profile, through over-expression of 
regeneration enhancing molecules can facilitate repair processes such as axonal growth, 
myelination and cellular organisation with improved survival of transplant populations [24, 
31–40, 60] whilst limiting undesirable systemic effects. Pre-clinical and early clinical data 
support the concept that such an approach offers significant benefits for functional 
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neurological recovery. Additionally, we have previously highlighted the significant benefits 
offered specifically by NSCs in such gene delivery approaches, given their role in neural cell 
replacement in transplantation therapies, release of therapeutic and immunosuppressive 
factors, and their migratory capacity (including toward sites of pathology) along with their 
demonstrated therapeutic potential in clinical trials [24, 60]. 
In terms of cell engineering, we have used a fusion of iron oxide nanoparticle based gene 
delivery with novel minicircle DNA vectors to genetically engineer the stem cells used here. 
Translation of genetically engineered cells into the clinic has traditionally been hampered by 
heavy reliance on viral mediated transfection which is associated with cytotoxicity, altered 
cell physiology and difficulty with scale up procedures [41–48]. The use of non-viral methods 
of transfection are thought to have higher translational relevance than viral vectors (given 
safety concerns with the latter), although are often associated with low transfection 
efficiencies. By contrast, MNP mediated gene delivery can be enhanced through application 
of oscillating magnetic fields to efficiencies near those of viruses (e.g. to a maximal efficiency 
of ca 55%, with transfection persisting up to 30 days, the last time point observed [24]). 
Minicircles also offer key advantages for biomedical gene engineering over other bacterial 
plasmids due to their smaller size, lack of antibiotic resistance genes and other potentially 
inflammatory sequences [24]. They have a higher transfection efficiency and reduced rates 
of transgene silencing, enabling longer term expression in engineered cells compared to 
conventional plasmids [24]. Minicircles are also easy to produce and both minicircles and 
MNP production can be scaled up for clinical applications. For therapeutic gene delivery, we 
have previously shown that NSCs can be nanoengineered to deliver a gene encoding a 
major neurotherapeutic factor brain derived neurotrophic factor/BDNF using our technology 
[49], with improved regenerative outcomes, highlighting the benefits of our approach for 
genetic modification of the stem cells used.  
To date, safety assessments of novel cell engineering technologies have often been 
relatively crude relying almost exclusively on analyses of cell number, viability and 
adherence and/or biochemical analysis such as the MTS assay. Indeed, the safety of 
nanoengineering protocols for NSCs using minicircle DNA vectors and nanoparticles has 
only been assessed using histological measures to date. Whilst such outcome measures are 
undoubtedly useful as first-stage readouts of the safety of nanoengineered cells, these 
cannot provide insights into subtle alterations in cellular physiology or the functional 
(regenerative) capacity of the cells. As such, it is essential for neuro-nanotechnology studies 
to develop safety screening systems/protocols for engineered transplant populations with 
enhanced orders of biological sophistication to evaluate their clinical translational potential. 
For our genetic engineering experiments using NSCs, we therefore considered it essential to 
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separate potential adverse effects associated with the cell engineering protocols from those 
related to biomaterial incorporation. To this end, we utilised a sophisticated proteomics 
based approach to gain a detailed insight into the physiological ‘normalcy’ of the engineered 
stem cells pre-incorporation.  
Using our advanced approach, we show that the magnetofection process had no discernible 
effect on key regenerative properties of the NSCs. To the best of our knowledge, this is the 
first proteomic investigation into the effects of magnetofection on the major transplant 
population of NSCs or indeed any cell type. A short (48 h) time point was used for the 
proteomics analyses as this coincides with the timing of peak GFP expression [41,42]; as 
such, it is reasonable to expect significant cellular and molecular changes at this time if the 
procedures were negatively impacting safety. In addition, a longer time point (96 h) was also 
used to examine molecular changes over time and which is in line with the time 
neurospheres have been cultured prior to transplantation (4-6 days [43,44]; 96 h post-
transfection is 5 days in culture). The use of mass spectrometry and bioinformatics based 
methods to examine potential perturbations to complex cellular behaviours, provides a highly 
detailed readout of the effect of MNPs, magnetofection protocols and MNP-delivered 
transgenes for transplantation therapy research. Further, the wide-scale analysis used here 
provides an unbiased approach unhindered by prior expectation, in contrast to antibody-
driven approaches, which by their very nature are target-driven. In addition, protein 
identification in Western blotting and ELISA requires specific antibodies which are not 
always available or are poorly characterised [47]. In this regard, mass spectrometry can 
measure and compare intensities of several different peptides per protein in contrast to the 
one band available for analysis in Western blotting. Mass spectrometry also combines a high 
linear dynamic range (up to 5 orders of magnitude linear dynamic range) with high sensitivity 
(femto- to attomole detection on-column) and mass resolving power (20,000 FWHM), 
meaning that broad, unbiased analyses can be performed with a high degree of quantitative 
certainty [48,50]. Use of retention time standards to enable normalisation of peak retention 
times improves alignment of large datasets and enhances our ability to make direct 
inferences between SWATH window information and peptide/protein identity and quantity. 
Therefore, we propose that the molecular approach described here can inform safe and 
effective neuro-nanomaterial design and MNP application strategies (e.g. use of magnetic 
fields) allowing for the systematic correlation of biomaterials' properties with safety outcome 
measures in stem cell transplant populations.  
Mass spectrometry results revealed limited changes in proteome profile following 
nanoengineering, where the vast majority of observed changes were attributable to 
biological differences between parallel experiments performed using different litters and time 
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points, with very few major alterations in protein expression being observed as a result of 
magnetofection. This unbiased proteome analysis revealed the reproducible observation in 
excess of 20,000 peptides from over 4000 proteins of a wide variety of gene ontologies, 
providing a wide and deep examination of proteome metrics. GFAP expression was shown 
to increase over time in both control and transfected cells from day 2 to 4. This may be 
expected as neurospheres are known to be composed of a heterogeneous cell population 
containing NSCs and some differentiating cells [51], so this increase could indicate ongoing 
differentiation in the neurospheres. However, we observed that the increase in GFAP 
expression over time in transfected samples was not as great as in control samples (2.4 fold 
less). As we did not see a difference in GFAP expression at day 2, the observed 
downregulation of GFAP in transfected samples compared to controls could be suggestive of 
a longer term effect of the nanoparticles on NSC differentiation. Another study has shown a 
reduction in GFAP expression in response to treatment with cerium oxide nanoparticles but 
this was performed after 10 days of NSC (C17.2 cells) differentiation [52]. The brain isoform 
of glycogen phosphorylase (PYGB) was also found to be downregulated in transfected cells 
at day 4. Glycogen storage and metabolism have been shown to be important for cell cycle 
maintenance and one study has shown this pathway is involved in regulating astrocyte 
proliferation [53]. This may also be suggestive of an effect on the astrocyte population within 
neurospheres – although we do not detect such an effect in our histological analyses. 
Mitochondrial pyruvate carrier 2 (MPC2) was found to be downregulated in transfected cells 
compared to control cells at day 2. MPC2 has a role in pyruvate metabolism and there is 
some evidence showing that pyruvate metabolism can influence stem cell differentiation [54]. 
However, other proteins within this pathway were not found to be dysregulated and this was 
not a sustained effect (no dysregulation was found by day 4). Finally, A0A171EBL2 or E3 
ubiquitin-protein ligase RNF213 was found to be upregulated in transfected cells at day 2. 
RNF213 has roles in ligase activity and ATPase activity and has been associated with 
vascular development and diseases such as Moyamoya disease [55]. No clear involvement 
in stem cell behaviour could be found for this protein. 
Overall, the proteomics data indicates that safe genetic engineering of NSCs can be 
accomplished using magnetofection and minicircle technology. In addition, we did not 
observe any effects of transfection and subsequent incorporation into Duragen PlusTM on key 
regenerative properties of NSCs including viability, stemness, proliferation and 
differentiation. Transgene expression was maintained in both the NSC population and in the 
daughter cells, albeit restricted to astrocytes. This suggests that, while further investigation is 
necessary, a multistep protocol involving magnetofection and stem cell encapsulation into 
Duragen PlusTM has the potential to be undertaken safely for clinical application.  
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Taken together, our data strongly support the concept of safely deploying a surgical grade 
and widely used biomaterial to develop implantable plugs of nanoengineered stem cells for 
combinatorial therapies in the damaged CNS and may also be applicable to a wide range of 
other neural transplant types. Indeed, recent work from our laboratory (unpublished data) 
suggest that the Duragen PlusTM matrix can also support the growth of the major transplant 
population of oligodendrocyte precursor cells, and their differentiation into oligodendrocytes 
with applications in demyelinating injuries of the brain and spinal cord. A critical but 
challenging next step will be robust molecular evaluation of the safety of stem cells 
engineered for neurotrophin release, and incorporated into a biomaterial matrix, which will 
require development of methods to isolate cells from the biomatrix. Further, as surgical 
grade materials in highly aligned conformations are developed for peripheral nerve injuries, 
we can predict similar advances will ensue with CNS materials that show mimicry of native 
spinal cord micro-architecture. We recently also showed that pre-labelling of transplant 
populations with clinical grade nanoparticles can be used to detect transplant cells 
incorporated into polymer matrices using magnetic resonance imaging [56], offering further 
advantages for clinical cell therapy. Further testing of such encapsulating matrices using live 
animal models of neurological injury with assessment of functional neurological recovery, 
and assessment of the compatibility of the biomaterials to support growth of human 
transplant populations is needed to advance the use of such an approach for clinical cell 
therapy applications. The next steps in evaluation of such novel cell- biomaterial constructs 
(ideally in chronic injuries with behavioural testing), will need to account for a number of 
confounding influences on transplant cell retention and survival. These include the impact of 
biomaterial breakdown and remodelling by incorporated transplant cells and host immune 
responses to the introduced constructs within neurological injury sites, whilst controlling for 
the potential regeneration enhancing properties of the material alone.  
4. Materials and Methods  
4.1 Reagents 
All culture grade plastics and culture medium reagents were from Thermo Fisher Scientific 
(Loughborough, UK) or Sigma Aldrich (Dorset, UK) unless otherwise specified. Human 
recombinant Epidermal Growth Factor (EGF) was from R&D Systems (Minnesota, USA) and 
human recombinant basic Fibroblast Growth Factor (FGF-2) was from Peprotech (London, 
UK). Fetal bovine serum was from Biosera (Nuiallé, France). Duragen PlusTM was a kind gift 
from Integra LifeSciences (New Jersey, USA). Calcein was from VWR (Pennsylvania, USA), 
Ethidium homodimer-1 and Hoechst were from Thermo Fisher Scientific, UK, and the Click-
iT EDU Imaging Kit was from Invitrogen (California, USA). Bovine serum albumin (BSA) and 
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paraformaldehyde (PFA) were from Thermo Fisher Scientific, normal donkey serum (NDS) 
was from Stratech Scientific (Suffolk, UK), and Triton X-100 was from Sigma Aldrich. 
Primary antibodies were anti-nestin from BD Biosciences (Oxford, UK), anti-sox-2 from 
Millipore (Massachusetts, USA), purified anti-neuron-specific class III beta-tubulin (TUJ1) 
from Biolegend (California, USA); anti-Glial Fibrillary Acidic Protein (GFAP) from Thermo 
Fisher Scientific; anti-Myelin Basic Protein (MBP) from BioRad (California, USA) and the 
TurboGFP antibody from Thermo Fisher Scientific. Secondary antibodies were Fluorescein 
isothiocyanate (FITC)-conjugated donkey anti-mouse, -rabbit and -rat, cyanine 3 (CY3) 
donkey anti-mouse, -rabbit and –rat which were all from Stratech Scientific. Vectashield 
mounting medium with 4’, 6-diamidino-2-phenylindole (DAPI) and Vectashield mounting 
medium for fluorescence were from Vector Laboratories (Peterborough, UK). 
pMC.EF1-MCS-IRES-GFP-SV40PolyA, GelRed, MC-EasyTM Growth Medium and MC-
EasyTM Induction Medium were from Cambridge Biosciences (Cambridge, UK). MC-EasyTM 
Minicircle DNA Production kit was from System Biosciences (California, USA). QIAprep 
miniprep kit and QIA maxiprep kit were from Qiagen (Manchester, UK). LB Agar and LB 
broth were from Thermo Fisher Scientific. Kanamycin was from Sigma Aldrich. EcoRI was 
from Promega (Wisconsin, USA). Agarose was from Appleton Woods (Birmingham, UK). 
NeuroMag transfection reagent was from Oz Biosciences (Marseilles, France) and the 
Magnefect-nano 24-magnet array system was from NanoTherics (Stoke-on-Trent, UK); see 
Pickard et al. [57] for nanoparticle and magnetic plate details.  
4.2. SEM characterisation of acellular Duragen PlusTM 
Samples were prepared using the osmium tetroxide (OsO4) and thiocarbohydrazide multiple 
step protocol known as OTOTO [58]. Samples were first fixed in 2.5% glutaraldehyde diluted 
in 0.1M Sodium Cacodylate buffer with 2mM calcium chloride for two h. All washes were 
carried out in Sodium Cacodylate buffer. After the first wash, samples were incubated with 
1% OsO4 for one hour then washed again. A series of four incubations followed this: (1) 
thiocarbohydrazide for 20 minutes then (2) OsO4 for two h, (3) thiocarbohydrazide for 20 
minutes, and (4) OsO4 for two h. Samples were then dehydrated in a series of ethanol 
solutions of increasing concentration. Critical point drying was carried out using liquid carbon 
dioxide. Samples were then mounted on aluminium stubs in preparation for SEM. SEM was 
carried out at the standard setting of 5Kv. Images were taken at x100, x1000 and x10,000 
magnification. For quantification of the pore size in Duragen PlusTM, five fields were taken at 
x1000 and included fields from the four corners and the centre of the Duragen PlusTM 




4.3 NSC culture 
Primary cultures of NSCs were derived from the subventricular zone of postnatal day one to 
three CD1 mice and propagated as neurospheres in accordance with previously published 
methods [42]. NSCs were passaged using an Accutase-DNaseI mix once confluent (six to 
ten days) and NSCs from passages 1-3 were used for experiments. Culture medium 
comprised of Dulbecco’s Modified Eagle Medium: Ham’s F12 (3:1), 4 ng/mL Heparin, 2% 
B27, 20 ng/mL Epidermal Growth Factor, 20 ng/mL basic Fibroblast Growth Factor, 50 U/mL 
penicillin and 50 U/mL streptomycin at 37°C (referred to from herein as neurosphere 
medium). Cultures underwent a 50% exchange of medium every two to three days.  
4.4 Incorporating NSCs into the Duragen PlusTM matrix 
To optimize the visualization of cells within Duragen PlusTM, the material required slicing to 
250 µm (data for optimization of thickness not shown) using a McIlwain Tissue Chopper 
under sterile conditions following a protocol adapted from Weightman et al. [59]. 
Neurospheres were dissociated (Accutase-DNaseI mix) and 300 µL seeded onto sliced 
samples of Duragen PlusTM in 24 well plates at a cell density of 1x106 cells/mL in 
neurosphere medium. NSC-seeded Duragen PlusTM samples were then incubated at 37°C in 
5% CO2/ 95% humidified air until fixation at the experimental time points (described in 
section 4.11). To investigate the effects of Duragen PlusTM on NSC differentiation, after 48    
h in neurosphere medium, this was exchanged for differentiation medium (components as 
for neurosphere medium minus growth factors with the addition of 1% fetal bovine serum) 
and samples underwent a 50% differentiation medium exchange every two to three days. 
4.5 Genetic engineering of NSCs 
mcGFP were produced using the parental plasmid pMC.EF1-MCS-IRES-GFP-SV40PolyA 
and the MC-EasyTM Minicircle DNA Production kit as per the manufacturer’s instructions 
using the E. coli strain ZYCY10P3S2T. Plasmid DNA was isolated using a QIAprep 
maxiprep kit as per the manufacturer’s instructions with the following amendments: 20 mL of 
Buffers P1, P2 and P3 were used. Conformation of plasmid size was performed using an 
EcoRI restriction digest and subsequent electrophoresis with a 1% agarose gel in 1xTAE 
buffer prestained with 0.0005% GelRed (2 h, 100V).  
The method of transfection of neurospheres used here has previously provided efficient 
transfection [24,60]. NSCs were passaged after reaching confluence using accutase and 
DNase as previously described, and 500 µL of a single cell suspension at 1 x105 cells/mL 
was added to each well of a 24-well Nunc non-treated multidish. NSCs were allowed 24    h 
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to form neurospheres prior to transfection. NeuroMag, a commercial MNP was used for all 
transfections. mcGFP and NeuroMag particles were suspended in a solution of 3:1 DMEM: 
F12 and incubated for 20 minutes to allow the formation of complexes. 50 µl of solution was 
added to each well for transfection containing 125 ng of mcGFP and 0.435 µl of NeuroMag 
iron oxide nanoparticles (a ratio used previously [42]), 50 µl of the same DMEM: F12 
solution without DNA or nanoparticles was added to each control well. Each plate was then 
placed on top of a nanoTherics magnefect-nano 24-magnet array system. The programme 
was set to F=4Hz to produce an oscillating field for 30 minutes. The plate was then removed 
and placed at 37°C in 5% CO2/ 95% humidified air. After 16 h, transfection of neurospheres 
was confirmed using an Axio Observer.Z1 in combination with an AxioCam MRm with Zen 
two. Following confirmation of transfection, neurospheres were either left to grow for two and 
four days before protein isolation was performed or transferred onto pre-prepared 250 µm 
slices of Duragen PlusTM. Constructs were then incubated at 37°C in 5% CO2/ 95% 
humidified air until their relevant assay time point. 
4.6 Isolation of proteins from genetically engineered NSCs and proteomic analysis 
Following transfection, NSCs were left to grow as neurospheres for two and four days along 
with untransfected control counterparts. Cells were washed 1X in PBS before dissociation 
using TrypLE (RT, <5 mins). Cells were then pelleted by centrifugation before washing 3X in 
50 mM Ammonium Bicarbonate (Ambic) with centrifugation in between each wash. After 
removal of the final wash, lysis buffer (100 µl; 0.1% Rapigest, 1% DNase made up in 50 mM 
Ambic) was added and probe sonication was performed on ice (3 cycles of 15 seconds on, 5 
seconds off, 20% power). Debris was removed by centrifugation and the protein content of 
the supernatant was determined using a Bradford assay. Protein concentrations were 
normalised to 100 µg for each sample. Each solution was then incubated with 10 mM DTT 
whilst shaking (80°C, 15 min) before addition of iodoacetamide (to a final concentration of 20 
mM, 30 min, RT and in the dark). Trypsin (2 µg) was then added to each sample and 
incubated at 37°C for 16 h. Remaining trypsin activity was terminated, and Rapigest 
precipitated, by addition of trifluoroacetic acid (1%) and acetonitrile (2%) with shaking (60°C, 
2 h). Rapigest was pelleted and removed by centrifugation and supernatant taken and stored 
at -80°C before further analysis.  
4.7 LC-MS/MS for Ion Library Creation and SWATH Acquisition 
IDA (information dependent acquisition) and SWATH MS were performed using a TripleTOF 
6600 mass spectrometer (SCIEX) coupled to a nanoLC 425 (SCIEX) operated in trap-elute 
configuration. Samples were loaded onto a YMC Triart C18 trap column (5 x 0.5 mm) at a 
flow rate of 10 µl/min for 4 minutes in 0.1% formic acid, 2% acetonitrile in water, before 
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being separated on a YMC Triart C18 column (3 µm, 0.3 x 150 mm) at 5 µl/min. For IDA 
analyses a linear gradient from 2 to 35% mobile phase B over 118 min was used, followed 
by 35 to 40% B over 5 min; for SWATH analyses a shorter gradient was employed: linear 
from 2 to 35% B over 38 min, followed by 35 to 40% B over 5 min. Mobile phases: A, 0.1% 
formic acid in water; B, 0.1% formic acid in acetonitrile. 4 µg sample plus 0.1 µl HRM 
calibration peptide standard (Biognosys, Zurich, Switzerland) was analysed per injection for 
SWATH analyses; for IDA analyses approximately 5 µg sample pool plus 0.125 µl HRM 
calibration peptides was analysed per injection. 
4.8 Ion library creation for SWATH Analysis 
An ion library for mining the SWATH data was created by combining IDA analysis of a 
pooled sample with a recent mouse adult αNSC ion library published by Braccia et al. [61]. 
For pooled sample analysis, IDA was combined with gas phase fractionation. The precursor 
ion m/z range of interest was divided into 5 sections, each containing an approximately 
equal number of precursors: m/z 400 – 487, 486 – 574, 573 – 677, 676 – 830 and 829 – 
1250. A separate IDA method was created for each gas phase fraction. A TOF MS survey 
scan (accumulation time 250 ms) was performed over the m/z range corresponding to the 
relevant gas phase fraction, followed by up to 50 dependent MS/MS scans (each with 
accumulation time 50 ms). MS/MS Spectra were acquired over the range 100 - 1500 m/z for 
precursors with charge state 2 – 5. Collision energies for MS/MS were calculated based on 
precursor size and charge using the SCIEX recommended rolling collision energy equations 
(https://sciex.com/community/application-discussions/proteomics/swath/data-
acquisition/crowdsourcing-optimized-rolling-collision-energy-curves-for-id-and-swath-
acquisition). The pooled sample was analysed twice using each IDA method. The combined 
data from the IDA analyses were submitted to database searching using ProteinPilot 
software (SCIEX) against a Uniprot mouse fasta database containing 83588 protein 
sequences (downloaded 24th May 2018). Protein identifications corresponding to the 
ProteinPilot 1% false discovery rate group (3490 proteins) were uploaded to the OneOmics 
data environment hosted on the BaseSpace cloud (http://basespace.illumina.com) via the 
CloudConnect microapplication for PeakView software (SCIEX). The αNSC library created 
by Braccia et al. [61] was also uploaded to BaseSpace. The two ion libraries were combined 
at the Extractor stage of OneOmics processing. 
4.9 SWATH MS DIA 
A variable window SWATH acquisition method was created using the SWATH Variable 
Window Calculator version 1.1 (SCIEX) based on TOF MS data of the pooled sample. The 
method contained 75 variable SWATH windows covering the precursor m/z range 400 – 
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1250. For each experimental cycle, a TOF MS scan with accumulation time 50 ms was 
performed over the m/z range 400 – 1250, followed by 75 SWATH MS/MS scans each with 
accumulation time 25 ms, m/z range 100 – 1500. Total cycle time was 1.98 sec. Collision 
energies for MS/MS were calculated as for IDA experiments, with a collision energy spread 
of 5V. Sample analysis order was randomised; each sample was analysed three times. 
4.10 SWATH MS Data analysis in OneOmics 
SWATH MS data was uploaded to BaseSpace using the CloudConnect microapplication for 
PeakView. 134,062 peptide transitions from 22,344 peptides were observed as having 
matches within the ion library used [61] et al, attributable to 4,107 proteins. Data were 
submitted to PeptideAtlas under identifier PASS01434. Using the Analytics module of 
OneOmics Cloud Browser (SCIEX, Framingham, MA), 213 proteins were reliably observed 
at a 65% confidence and 0.15 reproducibility across both conditions, both timepoints and all 
three litters.  
4.11 Characterisation of NSCs in Duragen PlusTM 
24 h, 8 days and 12 days after seeding NSCs in Duragen PlusTM, cell viability, proliferation 
and immunocytochemistry assays were performed. For transfected cells seeded into 
Duragen PlusTM, day 0 refers to the day of transfection and day 1 is when cells were added 
to the constructs. For differentiation, neurosphere medium was changed to differentiation 
medium at two days post transfection and one day post seeding into Duragen PlusTM. Here, 
transfected NSC behaviour was assayed at day 2 and differentiated cells assayed at day 9.  
To assess viability a live-dead assay was conducted which comprised 4 μM calcein, 6 μM 
ethidium homodimer-1, and 2 µg/mL Hoechst nuclear stain in phosphate buffered saline 
(PBS) incubated with samples for one hour. Proliferation assays were performed using a 
Click-iT EdU imaging kit according to the manufacturer’s instructions except where 
incubation times and washes were increased as follows: Component A was incubated for 16    
h with NSCs or differentiated cells in Duragen PlusTM. Constructs were then fixed with 4% 
PFA for 30 minutes. Samples were washed four times with 3% bovine serum albumin (BSA) 
in PBS then 0.5% Triton X-100 was added to each well for 40 minutes. Once again, the 
construct was washed four times with BSA. The EdU detection cocktail was prepared in 
accordance with the Invitrogen guidelines and incubated with the sample for one hour, 
protected from light. Constructs were washed in BSA twice and then PBS twice before the 
ICC protocol was carried out to identify nuclei and either nestin positive cells at 24 h or 
GFAP positive cells at eight days. 
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For identification of specific neural cell types and morphologies, immunocytochemistry was 
performed. Here, samples were incubated with 4% paraformaldehyde (PFA) for 20 minutes 
and then washed with PBS three times. Each sample was blocked for 30 minutes with a 
solution of 5% NDS in PBS-0.3% Triton X-100. Primary antibody diluted in blocker solution 
was added and incubated overnight. Following this, the primary antibody was removed, and 
the construct was washed with PBS three times for five minutes each. Again, the sample 
was blocked for a further 30 minutes with the blocker. Then an appropriate secondary 
antibody diluted in blocker (1:200) was added for up to three h, to allow penetration of 
Duragen PlusTM. Each sample was incubated with 2 µg/mL Hoechst for one hour before 
finally washing 3 times with PBS. Primary antibody dilutions were nestin (1:200) and Sox-2 
(1:1000) to detect NSCs, GFAP (1:500) for astrocytes, TUJ1 (1:1000) for neurons and MBP 
(1:200) for oligodendrocytes.  
4.12 Fluorescence microscopy of NSCs in Duragen PlusTM 
All fluorescence imaging was carried out using an Axio Observer.Z1 in combination with an 
AxioCam MRm (black and white camera) with Zen two (blue edition) software. For all assays 
five fields were randomly selected at x200 magnification. A stack of images was taken as the 
focus moved upwards to produce a Z-stack; this was carried out at each field with the 
interval fixed at 5 µm between each image. The top and bottom of the stack was allocated 
when the last visible cell went out of focus. 
4.13 Quantification and statistical analysis of histological data 
Quantification was carried out utilising ImageJ free software on stacks of images taken for 
live-dead assays, EdU assays, NSC markers and differentiation markers at the allotted time 
points. For quantification of axon length at day eight, 12 and 16, each Tuj 1 field was 
surveyed for axons extending within the same plane. Often due to the 3D nature of the 
construct axons would transverse the layers of the stack making measurements difficult. 
Axons were only selected for measurement if the cell body and full length of the axon could 
be visualised in one plane. Of the axons that met the stated criteria, the freehand line tool in 
ImageJ was utilised to mark from the cell body to the furthest point of the axon, following its 
curvature. This distance was measured. 
The cellular distribution was quantified in the vertical plane at 48 h and eight days. There 
were five fields per Duragen PlusTM sample as described above. The average number of 
cells per corner field or central field were calculated to determine if there was a preferential 
distribution in one of the sections. Analysis of the vertical distribution was also carried out by 
imaging cell nuclei. Z-stacks were imaged at 5µm intervals. The top and bottom of the matrix 
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was defined as the point where the first/ last fibre was in focus using phase microscopy. 
Nuclei per image were counted and converted to a percentage of the total number of images 
in that z-stack. The average number of cells at each one percent interval was calculated. 
Data is represented as mean ± the standard error of the mean with ‘n’ referring to the 
number of different cultures (derived from a different litter) within each experiment. Two 
sample T tests were used to compare between two groups. Grouped data was interrogated 
by a one-way analysis of variance (ANOVA) and Bonferroni’s multiple comparison test was 
used to determine statistical differences between groups. All statistical tests were performed 
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Supplementary results: Tables showing significantly dysregulated proteins between the 
indicated two experimental groups. 
 
Protein ID Fold change P-value 
tr|A0A171EBL2|A0A171EBL2_MOUSE 6.28 3.98E-03 
sp|Q9D023|MPC2_MOUSE -2.46 5.40E-05 
   
Supplementary Table 1: Transfected day 2 versus control day 2. 
Protein ID Fold change P-value 
sp|Q8CI94|PYGB_MOUSE -2.02 2.05E-03 
sp|P03995|GFAP_MOUSE -2.40 3.05E-05 
   
Supplementary Table 2: Transfected day 4 versus control day 4. 
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Protein ID Fold change P-value 
sp|P03995|GFAP_MOUSE 15.61 3.04E-06 
tr|Q58EU7|Q58EU7_MOUSE 5.97 1.24E-03 
tr|Q3UYM8|Q3UYM8_MOUSE 10.25 1.50E-03 
sp|Q8JZU2|TXTP_MOUSE 8.84 1.79E-04 
tr|Q3TVI6|Q3TVI6_MOUSE 6.91 1.65E-04 
tr|Q3USR5|Q3USR5_MOUSE 5.71 4.53E-05 
tr|Q3UJK6|Q3UJK6_MOUSE 5.65 2.26E-03 
sp|Q9DBL1|ACDSB_MOUSE 5.61 7.32E-03 
sp|Q9CQE8|CN166_MOUSE 5.50 8.34E-04 
sp|Q8CI94|PYGB_MOUSE 5.50 2.86E-06 
sp|Q80YN3|BCAS1_MOUSE 5.09 3.78E-03 
tr|Q6S393|Q6S393_MOUSE 4.68 1.82E-04 
tr|Q8C7W8|Q8C7W8_MOUSE 4.55 5.58E-03 
tr|Q3TYV5|Q3TYV5_MOUSE 4.54 1.98E-03 
tr|Q3UYH9|Q3UYH9_MOUSE 4.15 1.35E-03 
tr|Q3UFX6|Q3UFX6_MOUSE 4.08 8.23E-03 
tr|Q4FJX4|Q4FJX4_MOUSE 3.90 3.31E-04 
sp|O88587|COMT_MOUSE 3.60 4.01E-03 
sp|P12382|PFKAL_MOUSE 3.31 4.86E-04 
sp|Q9D023|MPC2_MOUSE 3.71 9.57E-03 
sp|P70271|PDLI4_MOUSE 3.62 7.47E-05 
tr|Q3V1S0|Q3V1S0_MOUSE 3.61 1.63E-05 
sp|Q9QYG0|NDRG2_MOUSE 3.44 6.73E-03 
sp|P14873|MAP1B_MOUSE 3.38 3.41E-06 
sp|P16330|CN37_MOUSE 3.24 1.63E-03 
tr|Q3V1C8|Q3V1C8_MOUSE 2.20 4.46E-03 
sp|Q9EQ20|MMSA_MOUSE 3.13 1.83E-04 
sp|Q61738|ITA7_MOUSE 2.70 1.28E-06 
sp|P17751|TPIS_MOUSE 2.67 6.40E-04 
tr|Q4VA29|Q4VA29_MOUSE 2.27 6.43E-03 
tr|Q80UE5|Q80UE5_MOUSE 2.70 2.46E-03 
tr|Q8BRQ9|Q8BRQ9_MOUSE 2.56 1.72E-04 
tr|Q3UXR4|Q3UXR4_MOUSE 2.48 1.32E-08 
sp|Q9ESW8|PGPI_MOUSE 2.35 5.33E-03 
sp|Q9Z0R9|FADS2_MOUSE 2.33 1.82E-04 
sp|P26443|DHE3_MOUSE 2.33 1.94E-05 
tr|Q6GT24|Q6GT24_MOUSE 2.32 4.90E-03 
sp|Q99L13|3HIDH_MOUSE 2.10 1.91E-03 
sp|P26040|EZRI_MOUSE 2.27 1.44E-06 
sp|Q9R0H0|ACOX1_MOUSE 2.07 2.97E-03 
sp|Q01320|TOP2A_MOUSE -5.87 6.67E-05 
sp|Q8VDF2|UHRF1_MOUSE -3.81 1.93E-04 
tr|Q52L97|Q52L97_MOUSE -2.64 2.53E-03 
sp|P49717|MCM4_MOUSE -3.75 5.78E-03 
tr|Q3ULD6|Q3ULD6_MOUSE -2.94 8.88E-06 
tr|Q52KC3|Q52KC3_MOUSE -2.53 5.41E-04 
tr|Q542I2|Q542I2_MOUSE -2.40 2.38E-03 
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sp|Q61881|MCM7_MOUSE -2.68 2.08E-04 
tr|Q91ZH2|Q91ZH2_MOUSE -2.33 5.16E-07 
tr|Q8BQ03|Q8BQ03_MOUSE -2.43 6.96E-07 
sp|P97311|MCM6_MOUSE -2.35 5.74E-03 
tr|A2AGS6|A2AGS6_MOUSE -2.13 2.05E-07 
sp|Q8CG48|SMC2_MOUSE -2.04 2.28E-03 
tr|Q99JW7|Q99JW7_MOUSE -3.34 7.02E-07 
tr|Q3U3F6|Q3U3F6_MOUSE -2.07 3.54E-04 
sp|P13864|DNMT1_MOUSE -2.40 1.85E-04 
sp|E9Q5C9|NOLC1_MOUSE -2.13 1.23E-05 
sp|Q8VD75|HIP1_MOUSE -2.15 4.51E-05 
tr|Q497K3|Q497K3_MOUSE -4.55 1.05E-04 
Supplementary Table 3: Control day 4 versus control day 2. 
Protein ID Fold change P-value 
sp|P03995|GFAP_MOUSE 8.84 7.66E-05 
sp|Q8CI94|PYGB_MOUSE 2.91 5.06E-04 
sp|Q9D023|MPC2_MOUSE 4.32 5.09E-06 
tr|Q3UFX6|Q3UFX6_MOUSE 3.52 3.12E-03 
tr|Q3USR5|Q3USR5_MOUSE 2.65 3.63E-03 
sp|O89023|TPP1_MOUSE 2.51 4.07E-06 
sp|Q9QYG0|NDRG2_MOUSE 2.41 6.88E-03 
tr|Q3UYH9|Q3UYH9_MOUSE 2.27 5.60E-03 
tr|Q6S393|Q6S393_MOUSE 2.19 7.73E-03 
tr|Q544Z7|Q544Z7_MOUSE 2.93 3.26E-03 
sp|Q9Z0R9|FADS2_MOUSE 2.68 4.06E-03 
tr|Q8BRQ9|Q8BRQ9_MOUSE 2.40 9.01E-03 
sp|O09005|DEGS1_MOUSE 2.04 1.68E-04 
tr|A0A1Y7VN70|A0A1Y7VN70_MOUSE 2.35 5.03E-04 
sp|P12382|PFKAL_MOUSE 2.39 1.46E-10 
tr|Q497K3|Q497K3_MOUSE -3.57 7.76E-04 
sp|P33609|DPOLA_MOUSE -2.33 2.05E-03 
sp|P49717|MCM4_MOUSE -2.28 1.01E-03 
sp|Q8VDF2|UHRF1_MOUSE -2.58 1.52E-05 
sp|Q01320|TOP2A_MOUSE -2.38 9.08E-09 
Supplementary Table 4: Transfected day 4 versus transfected day 2. 
 
